Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados

Abstract

Objective: to describe the efficacy of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer in Hospital de San José, Bogotá, Colombia, between 2016 and 2020. Materials and methods: a descriptive historical cohort study in patients with epithelial ovarian cancer managed with complete surgical cytoreduction followed by 6 carboplatin-paclitaxel chemotherapy cycles. The follow-up time was approximately 1 year. Results: out of the 45 studied patients managed with optimal cytoreduction followed by adjuvant chemotherapy, cancer progression was observed in 13/45 (29%) cases, 2/45 (4%) showed partial response and 30/45 (66.6%) showed complete response. Chemotherapy-related adverse effects occurred in (n = 45/45, 100%), including alopecia (n = 45/45, 100%), nausea and vomiting (n = 30/45, 67%), arthralgia (n = 10/45, 22%), peripheral neuropathy reported as hands and feet paresthesia (n = 6/45, 13%) and one case (2%) had grade I hematologic toxicity (mild neutropenia). Conclusions: 66.6% of patients with epithelial ovarian cancer treated with optimal cytoreduction and adjuvant chemotherapy exhibited complete response to chemotherapy with better tolerance to chemotherapy (carboplatin-paclitaxel) related adverse effects.